Lung Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030

Molecular Test is the fastest growing segment, North America is the largest market globally

The Global Lung Cancer Diagnostics Market, valued at USD 1.54 Billion in 2024, is projected to experience a CAGR of 6.99% to reach USD 2.31 Billion by 2030. The Global Lung Cancer Diagnostics Market encompasses a diverse range of technologies and procedures utilized for the early detection and precise characterization of lung cancer. Market growth is primarily driven by the escalating global incidence of lung cancer and heightened awareness surrounding the benefits of early screening.

Key Market Drivers

The increasing global incidence of lung cancer represents a fundamental driver for the diagnostics market. This rising number of new cases directly necessitates expanded diagnostic capabilities for early detection and precise staging, which are vital for effective treatment planning and improved patient outcomes. The escalating incidence creates continuous demand on healthcare systems for accessible diagnostic tools, encompassing advanced imaging modalities and comprehensive molecular profiling. According to the American Cancer Society and the International Agency for Research on Cancer, in April 2024, "Global Cancer Statistics, 2024" reported an estimated 2.5 million cases of lung cancer were newly diagnosed worldwide in 2022.

Key Market Challenges

The substantial capital investment required for advanced diagnostic technologies poses a notable challenge to the expansion of the Global Lung Cancer Diagnostics Market. The high acquisition, installation, and ongoing maintenance costs associated with state-of-the-art imaging equipment, advanced molecular profiling platforms, and specialized laboratory infrastructure significantly limit their widespread accessibility and adoption. This financial barrier is particularly impactful in emerging economies, where healthcare budgets are often constrained and robust medical infrastructure is less developed.

Key Market Trends

The expansion of global lung cancer screening programs represents a significant trend driving the diagnostics market by systematically increasing the early detection of the disease. These initiatives, increasingly backed by updated guidelines, broaden the eligible population for low-dose computed tomography (LDCT) screening, leading to a greater demand for imaging equipment, skilled radiologists, and subsequent diagnostic procedures. For instance, according to the American Cancer Society, in June 2024, a study found that the up-to-date lung cancer screening prevalence in the United States was 18.1% in 2022, highlighting ongoing efforts to improve screening rates. This programmatic expansion ensures that more individuals at high risk are undergoing regular examinations, facilitating earlier diagnosis and intervention.

Key Market Players Profiled:

• Sanofi S.A.
• Roche Diagnostics Corporation
• BioMérieux SA
• Qiagen N.V.
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.
• AstraZeneca plc
• Illumina Inc.
• Johnson & Johnson
• Abbott Laboratories Inc.

Report Scope:

In this report, the Global Lung Cancer Diagnostics Market has been segmented into the following categories:

By Type:

• Small Cell Lung Cancer
• Non-small Cell Lung Cancer

By Test:

• Imaging Test
• Biopsy
• Sputum Cytology
• Molecular Test
• Others

By Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lung Cancer Diagnostics Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.